TechnoDerma Announced New Progress in Phase I Clinical Trials of TDM-105795 in the U.S.

News

}

Home / News / Portfolio Highlights / Portfolio Highlights detail

Time: 2021-05-11

Source: Viva Biotech

[Abstract]:It is expected that the phase I clinical dose-climbing trial will be completed in about three months.

San Diego, USA-Recently, Jiaxing TechnoDerma Medicines Inc., a biotech company invested and incubated by Viva BioInnovator, announced that its phase I clinical trial of the world's leading small molecule drug TDM-105795 was successfully completed the first human administration (FIH) in healthy male subjects with androgenetic alopecia (AGA) in the skin clinical research center-TCR (Therapeutics Clinical Research), San Diego, U.S..

TDM-105795 is a world-leading small molecule drug to treat the androgenetic alopecia with global intellectual property protection. At present, the phase I clinical trial of TDM-105795 has completed the subject screening, enrollment, and the first two subjects administration. It is expected that the phase I clinical dose-climbing trial will be completed in about three months.

Previous Page：Anji Pharma Launches Phase 3 Trial for ANJ900 Next Page：Shanghai EPN and BioMap Reached a Strategic Cooperation

Back

Media contact: vivapr@vivabiotech.com

This site uses cookies and your privacy choices are important to us

We use cookies to improve the user experience and to analyze website traffic. By clicking "Accept", you consent to the use of cookies on our website, such as cookies policies.